CDI, the result of intensive efforts and advances developed by the High-Throughput Biology Center at Johns Hopkins University, is a privately owned research and discovery company in the field of proteomics.

The company was created by scientists for scientists, addressing the critical needs required in order to accelerate research, advance discoveries and translate these discoveries into novel products and services that improve human health.

The company applies its accelerating platforms to internal, collaborative, and client programs.

  • Service and technology dissemination provide immediate revenue.
  • Internal programs create a pipeline of proprietary biomarker panels and soon-to-be diagnostic and predictive tools in the fields of autoimmunity, oncology, therapeutic outcome and toxicity prediction.

Management

  • image description

    Dr. Ignacio Pino, Director, CEO and Co-founder. Dr. Pino is a veterinary doctor by training and an entrepreneur by vocation. For the last 8 years he has led CDI’s growth path.

  • image description

    Scott Paschke, Biochemist. Scott is CDI’s VP of Sales and Business Development. He has over 20 years of experience in the biotechnology sector working with renowned R&D reagent companies.

  • image description

    Daniel Eichinger, Co-founder. Dan is CDI’s Chief Scientific Officer. He was the former chair of the Department of Parasitology at NYU Medical School. He is a monoclonal antibody development and recombinant protein development and production expert.

Board of Directors

  • image description

    Jef Boeke, CDI Co-founder. Jef is the director of the Institute of Synthetic Genetics at NYU. He founded the HiT Center at Johns Hopkins.

  • image description

    Joe Bonaventura, CDI Co-founder. Joe is a serial inventor and a retired biochemist from Duke University

  • image description

    Paul Horan, Former VP Business Development at GTC Bio. He is also a founding partner at QED Technologies and Zynaxis. Paul has extensive knowledge in the diagnostics field.

  • image description

    Antoine de Marsily, Vice President of Grupo VL and former VP of Operations of MOVA Pharmaceuticals. He represents Apollo Ventures which is the lead investor of CDI’s Series A round.

Scientific Advisors

Dr. Heng Zhu:
Heng is a CDI Co-founder. He is a professor in the Department of Pharmacology at Johns Hopkins Medical School. He is one of the inventors of high-density protein microarrays.
Dr. Seth Blackshaw:
Seth is a CDI Co-founder. Together with Dr. Zhu he was responsible for building the HuProt array prototype. He is a professor of neuroscience, neurology and ophthalmology at Johns Hopkins University School of Medicine.
Dr. Jiang Qian:
Jiang is a CDI advisor in the area of bioinformatics. He is an associate professor of ophthalmology at the Wilmer Eye Institute.
Dr. Prashant Desai:
Prashant is a CDI advisor and collaborator in the area of virology and an associate professor in the Department of Oncology at Johns Hopkins University.
Dr. Joel Bader:
Joel is a professor in the Biomedical Engineering program at Johns Hopkins University. One of his main areas of interest is algorithms to discover modules in networks, anchoring protein pathways with genetic screens and whole genome association. Joel consults CDI on database development and management related to CDI recombinant protein collections.